Literature DB >> 31053884

The effect and molecular mechanism of statins on the expression of human anti-coagulation genes.

Sheng-Nan Chang1,2,3, Cho-Kai Wu2, Ling-Ping Lai2, Fu-Tien Chiang2,4, Juey-Jen Hwang1,2, Chia-Ti Tsai5,6,7.   

Abstract

Statins are potent lipid-lowering drugs. Large prospective clinical trials have shown the anti-thrombotic effect of statins, e.g., preventing deep vein thrombosis. However, the mechanism underlying the beneficial effect of statins in reducing thrombus formation remains to be established. We, thus, conduct this study to investigate the potential molecular mechanisms. The cultured human hepatoma cells (HepG2) were used as the in vitro model. The human protein C gene promoter was cloned into the luciferase reporter to study the transcriptional regulation of human protein C gene. Wistar rats fed with simvastatin (5 mg/kg day) were used as the in vivo model. We found that simvastatin increased the expression of protein C in hepatocytes (361 ± 64% and 313 ± 59% after 2 h and 6 h of stimulation, respectively, both p < 0.01). In the animal study, the serum protein C levels were increased in the simvastatin-treated group (7 ± 2.2 unit/ml vs 23.4 ± 19.3 unit/ml and 23.4 ± 18.2 unit/ml and 1 and 2 weeks of treatment, respectively, both p < 0.05). Regarding the possible molecular mechanism, we found that the level of hepatocyte nuclear factor 1α (HNF1α) was also increased in both the in vivo and in vitro models. We found that the protein C promoter activity was increased by simvastatin, and this effect was inhibited by HNF1α knockdown and constitutively active Rac1. Therefore, stains may modulate protein C expression through small GTPase Rac 1 and HNF1α.

Entities:  

Keywords:  Anti-coagulation; Gene; HNF 1α; Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase; Protein C; Rac1

Mesh:

Substances:

Year:  2019        PMID: 31053884     DOI: 10.1007/s00018-019-03100-w

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  44 in total

1.  Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity.

Authors:  C A Spek; R M Bertina; P H Reitsma
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

Review 2.  Modulation of coagulation and fibrinolytic pathways by statins.

Authors:  Masato Eto; Thomas F Luscher
Journal:  Endothelium       Date:  2003

3.  HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.

Authors:  C J M Doggen; R N Lemaitre; N L Smith; S R Heckbert; B M Psaty
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

4.  Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.

Authors:  G Dangas; J J Badimon; D A Smith; A H Unger; D Levine; J H Shao; P Meraj; C Fier; J T Fallon; J A Ambrose
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

Review 5.  Statin therapy and stroke prevention.

Authors:  C J Vaughan; N Delanty; C T Basson
Journal:  Curr Opin Cardiol       Date:  2001-07       Impact factor: 2.161

6.  Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.

Authors:  D Grady; N K Wenger; D Herrington; S Khan; C Furberg; D Hunninghake; E Vittinghoff; S Hulley
Journal:  Ann Intern Med       Date:  2000-05-02       Impact factor: 25.391

7.  Use of statins and the subsequent development of deep vein thrombosis.

Authors:  J G Ray; M Mamdani; R T Tsuyuki; D R Anderson; E L Yeo; A Laupacis
Journal:  Arch Intern Med       Date:  2001-06-11

8.  Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation.

Authors:  A Undas; K E Brummel; J Musial; K G Mann; A Szczeklik
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

9.  Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.

Authors:  Francesco Cipollone; Andrea Mezzetti; Ettore Porreca; Concetta Di Febbo; Michele Nutini; Maria Fazia; Angela Falco; Franco Cuccurullo; Giovanni Davì
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

10.  Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.

Authors:  Michele Cortellaro; Elisabetta Cofrancesco; Eloisa Arbustini; Francesca Rossi; Andrea Negri; Eiena Tremoli; Livio Gabrielli; Marina Camera
Journal:  Thromb Haemost       Date:  2002-07       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.